EMA Refused: Lympreva (dasiprotimut-t) — Biovest Europe Ltd

View source ↗

Summary

EMA refused approval for Lympreva (dasiprotimut-t) by Biovest Europe Ltd for lymphoid malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Lympreva (dasiprotimut-t)

Snippet

Status: Refused. Therapeutic area: Lymphoma, Non-Hodgkin. MAH: Biovest Europe Ltd. Decision date: 03/07/2015. Orphan medicine